Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
ATR senses stiff extracellular matrix to promote epithelial-to-mesenchymal transition and immune suppression
Xinyi Tu, Xiangyu Zeng, Yaoliang Sun, Yaobin Ouyang, Lingling Zhu, Ping Yin, Kevin Pavelko, Roberto Leon-Ferre, Yanxia Jiang, Haidong Dong, Jodi Carter, Shouhai Zhu, Jann N. Sarkaria, Liewei Wang, Jinzhou Huang, Kuntian Luo, Yiqun Han, Zheming Wu, Zhenkun Lou, Robert W. Mutter
Xinyi Tu, Xiangyu Zeng, Yaoliang Sun, Yaobin Ouyang, Lingling Zhu, Ping Yin, Kevin Pavelko, Roberto Leon-Ferre, Yanxia Jiang, Haidong Dong, Jodi Carter, Shouhai Zhu, Jann N. Sarkaria, Liewei Wang, Jinzhou Huang, Kuntian Luo, Yiqun Han, Zheming Wu, Zhenkun Lou, Robert W. Mutter
View: Text | PDF
Research Article Cell biology Immunology Oncology

ATR senses stiff extracellular matrix to promote epithelial-to-mesenchymal transition and immune suppression

  • Text
  • PDF
Abstract

Our research uncovers a role for ATR in responding to ECM stiffness and promoting epithelial-to-mesenchymal transition (EMT) and metastasis. ATR, when deubiquitinated and upregulated by USP21 under enhanced ECM stiffness conditions, phosphorylates the nuclear protein SUN2, which promotes β-catenin nuclear translocation and EMT. ATM-mediated EMT promotes polymorphonuclear myeloid-derived suppressor cell recruitment and inhibits CD103+ dendritic cells, fostering an immunosuppressive tumor milieu. ATR inhibition disrupts this malignant cascade by promoting mesenchymal-to-epithelial transition to enhance antitumor immunity and mitigate metastases. Consistently, circulating HLA-DR+ dendritic cells were also enhanced following treatment with the ATR inhibitor berzosertib in patients with therapeutically resistant early-stage breast cancer. Our data suggest that ATR-targeted therapy may be optimized by considering both DNA damage–dependent and EMT-inducing effects of ATR

Authors

Xinyi Tu, Xiangyu Zeng, Yaoliang Sun, Yaobin Ouyang, Lingling Zhu, Ping Yin, Kevin Pavelko, Roberto Leon-Ferre, Yanxia Jiang, Haidong Dong, Jodi Carter, Shouhai Zhu, Jann N. Sarkaria, Liewei Wang, Jinzhou Huang, Kuntian Luo, Yiqun Han, Zheming Wu, Zhenkun Lou, Robert W. Mutter

×

Figure 7

The phosphorylation of SUN2 by ATR facilitates the nuclear translocation of β-catenin.

Options: View larger image (or click on image) Download as PowerPoint
The phosphorylation of SUN2 by ATR facilitates the nuclear translocation...
(A–F) ATR knockdown, ATR inhibition with VX970, or SUN2 knockdown reduces β-catenin nuclear localization in MDA-MB-231 cells, as determined by nuclear-cytoplasmic fractionation and immunoblotting. Quantification was performed using 1-way ANOVA or Student’s t test (n = 3). (G–J) SUN2 knockdown or ATR inhibition reduces the association of α-catenin with β-catenin and KASH2. Protein interactions were assessed by α-catenin immunoprecipitation followed by immunoblotting. Data were analyzed by 2-way ANOVA (n = 3). (K and L) SUN2 knockdown decreases β-catenin recruitment to the ZEB1 and SNAIL1 promoter regions, as determined by ChIP-qPCR. Statistical significance was assessed using 1-way ANOVA (n = 3). (M) ATR knockdown reduces the expression level of ZEB1 and Snail1. MDA-MB-231 cells infected with lentivirus encoding control or shATR were harvested, and the mRNA levels of ZEB1 and Snail were detected by RT-qPCR (n = 3). Statistical analysis was performed using 1-way ANOVA. (N) SUN2 knockdown reduces the expression level of ZEB1 and Snail1. MDA-MB-231 cells infected with lentivirus encoding control or shSUN2 were harvested, and the mRNA level of ZEB1 and Snail was detected using RT-qPCR (n = 3). Statistical analysis was performed using 1-way ANOVA. (O and P) MDA-MB-231 cells infected with lentiviruses encoding control, shSUN2, shATR, or both shSUN2 and shATR were harvested for RNA extraction, and the expression of ZEB1 and Snail was subsequently assessed. Statistical analysis was performed using 1-way ANOVA. (Q) ATR expression level is positively correlated with ZEB1 and Snail1. The data were extracted from the TCGA database. All statistical data represent biological replicates, and results are expressed as mean ± SD. Western blot and co-IP experiments were independently repeated at least 3 times with similar results.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts